Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
© 2022. The Author(s)..
PURPOSE OF REVIEW: Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain serum urate levels below 6 mg/dL, and these patients, thus classified as having refractory or uncontrolled gout, often require therapy with pegloticase to reduce symptoms and tophaceous burden. The objective of this expert opinion review is to summarize the available evidence supporting the use of concomitant immunomodulators with pegloticase to prevent development of anti-drug antibodies (ADAs) when treating patients with uncontrolled gout.
RECENT FINDINGS: Emerging evidence suggests that adding an immunomodulator to pegloticase therapy can substantially increase response rates to double those observed in phase 3 randomized controlled trials. The combination of immunomodulation with pegloticase should be considered in routine clinical practice to improve durability of response, efficacy, and safety among patients with uncontrolled gout who otherwise have limited therapeutic options.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current rheumatology reports - 24(2022), 1 vom: 15. Jan., Seite 12-19 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Botson, John K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 09.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11926-022-01055-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336990928 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336990928 | ||
| 003 | DE-627 | ||
| 005 | 20231225233411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11926-022-01055-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM336990928 | ||
| 035 | |a (NLM)35167037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Botson, John K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 09.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a PURPOSE OF REVIEW: Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain serum urate levels below 6 mg/dL, and these patients, thus classified as having refractory or uncontrolled gout, often require therapy with pegloticase to reduce symptoms and tophaceous burden. The objective of this expert opinion review is to summarize the available evidence supporting the use of concomitant immunomodulators with pegloticase to prevent development of anti-drug antibodies (ADAs) when treating patients with uncontrolled gout | ||
| 520 | |a RECENT FINDINGS: Emerging evidence suggests that adding an immunomodulator to pegloticase therapy can substantially increase response rates to double those observed in phase 3 randomized controlled trials. The combination of immunomodulation with pegloticase should be considered in routine clinical practice to improve durability of response, efficacy, and safety among patients with uncontrolled gout who otherwise have limited therapeutic options | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antidrug antibodies | |
| 650 | 4 | |a Gout | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Immunomodulation | |
| 650 | 4 | |a Pegloticase | |
| 650 | 7 | |a Gout Suppressants |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Urate Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.7.3.3 |2 NLM | |
| 650 | 7 | |a Pegloticase |2 NLM | |
| 650 | 7 | |a R581OT55EA |2 NLM | |
| 700 | 1 | |a Baraf, Herbert S B |e verfasserin |4 aut | |
| 700 | 1 | |a Keenan, Robert T |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, John |e verfasserin |4 aut | |
| 700 | 1 | |a Masri, Karim R |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Jeff |e verfasserin |4 aut | |
| 700 | 1 | |a Yung, Christianne |e verfasserin |4 aut | |
| 700 | 1 | |a Freyne, Brigid |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Abdellatif, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Soloman, Nehad |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, N Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Strand, Vibeke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current rheumatology reports |d 1999 |g 24(2022), 1 vom: 15. Jan., Seite 12-19 |w (DE-627)NLM110373642 |x 1534-6307 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:12-19 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11926-022-01055-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 1 |b 15 |c 01 |h 12-19 | ||